Biocure Technology Inc. (TSE:CURE) has released an update.
Biocure Technology Inc. has announced an extension for finalizing its strategic transaction with Atriva Therapeutics, moving the deadline from March 31, 2024, to June 30, 2024, as both companies continue their due diligence processes. During this period, Biocure’s shares will remain halted until the transaction is complete. This collaboration marks a significant milestone for Biocure, potentially impacting its operational and financial future.
For further insights into TSE:CURE stock, check out TipRanks’ Stock Analysis page.
